Invitrogen and Signalomics to Co-Develop Cancer Diagnostic Reagents | GenomeWeb

NEW YORK, April 11 (GenomeWeb News) - Invitrogen and Signalomics of Germany will collaborate to develop nanocrystal reagents for cancer diagnostics, Invitrogen said today.


Initially, the partners want to develop an imaging agent that can be used to identify colon carcinomas that require surgery.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.